{"prompt": "['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 40 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', '6.2', 'DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS', '6.2.1', 'Screening and run-in period(s)', 'Screening Period', 'Visit 0 - Informed consent (at least 7 days before Visit 1)', 'Informed consent will be obtained prior to patient participation in the trial, which', 'includes any medication wash-out procedures or restrictions as well as HRCT transfer', 'to central review. Upon obtaining informed consent, the patient will be instructed on', 'the medication washout and other restrictions needed, and dispensed an eDiary (or', 'eDiary application for own device) and activity monitor if they meet the inclusion and', 'exclusion criteria at this time.', 'A preliminary check of in-/exclusion criteria is recommended at time of informed', 'consent to avoid unnecessary procedures in non-eligible patients.', 'Confirmation that the patient is being treated with nintedanib for up to 30 months', 'will be confirmed via medical records, observation of the patient prescription', 'medication, or medical records will be requested to confirm. Patients who have', 'recently started nintedanib 150 mg BID and have started by the day of randomization', 'must be on nintedanib 150 mg BID a minimum of 10 days by the first day of', 'pulmonary rehabilitation.', 'An HRCT not older than 24 months will be sent for central calculation of QLF, to', 'assess HRCT pattern for patient characterization. Provided the patient meets all other', 'eligibility criteria, the HRCT can be performed for the purposes of participation in the', 'trial if the patient does not have a HRCT within 24 months, at the time of the', 'scheduled Visit 2.', 'Site personnel will perform a screening call in IRT to ensure accurate tracking of trial', 'participation.', 'Visit 1', 'Demographics', 'Medical history including pre-existing conditions', 'Medication records needed for confirmation that the patient has been treated with', 'nintedanib for up to 30 months will be reviewed at this visit if not available at consent', 'visit Patients who have recently started nintedanib 150 mg BID and have started by', 'the day of randomization must be on nintedanib 150 mg BID a minimum of 10 days', 'by the first day of pulmonary rehabilitation.', 'Any adverse events (since consent, if applicable)', 'SGRQ, KBILD and UCSD SOBQ will be completed by the patient, prior to any', 'procedures', 'Collect and download/review PROactive Tool from eDiary and activity monitor data', 'Physical examination including vital signs', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']['Boehringer Ingelheim', '16 Dec 2019', 'BI Trial No.: 1199-0324', 'c19558808-06', 'Clinical Trial Protocol', 'Page 41 of 103', 'Proprietary confidential information \u00a9 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies', \"A resting 12-lead electrocardiogram using site's own equipment will be performed\", 'and evaluated by the Investigator (if possible prior to blood draw)', 'Resting SP02', \"FVC measurements will be conducted using the site's own equipment, per the\", 'instructions in Section 5.1.2.3', 'DLco measurement will be conducted. FVC measurement has to be done first,', \"followed by patient's rest and subsequent DLco measurement\", 'Blood and urine samples (safety lab and serum pregnancy if woman of child bearing', 'potential) will be collected and submitted to the local laboratory (for details refer to', 'Section 5.2.3). Prior to blood draw a pre-assessment of all inclusion and exclusion', 'criteria is highly recommended', 'Practice 6 minute walk test', 'Incremental and practice work rate cycle ergometry test performed at the clinic at end', 'of Visit 1', 'Send HRCT to central calculation of QLF if available, or schedule patient for HRCT', 'if not available', 'For patients qualified to enter the screening period, patients will be dispensed an', 'eDiary (or eDiary application for own device) and activity monitor and instructed on', 'the use of both devices, with specific instructions given to use both devices for 7 days', 'prior to Visit 2', 'Visit 2 will be scheduled', 'If patient fails screening, IRT call to discontinue patient', '6.2.2', 'Treatment period(s)', 'Treatment phase will be a 24 week period, beginning at visit 2.', 'Visits are planned after 3, 6, 12, 18 and 24 weeks after randomization. If additional time is', 'needed after randomization to schedule the pulmonary rehabilitation for a patient randomized', 'to that group, the time between visits 2 and 3 may be extended up to 6 weeks. The visit', 'schedule will resume on the day of the first pulmonary rehabilitation visit, and all subsequent', 'visits will be scheduled accordingly to keep the time between visits per protocol and a total', '24 week treatment period.', \"During all the visits it is important that patients' questionnaires are completed before any\", 'other procedure. The order of the other procedures to be followed is given below as an', 'indication but can be adapted for practical reasons.', '001-MCS-40-106-RD-03 (14.0) / Saved on: 17 October 2016']\n\n###\n\n", "completion": "END"}